COX-2 is not required for the development of murine chronic pancreatitis

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 300, Issue 6, 2011, Pages

  Silva, Alberto ^a   Weber, Achim ^a   Bain, Martha ^a   Reding, Theresia ^a   Heikenwalder, Mathias ^b   Sonda, Sabrina ^a   Graf, Rolf ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Fibrosis; Pancreatic inflammation; Tissue damage

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CERULETIDE; COLLAGEN; CYCLOOXYGENASE 2; MESSENGER RNA; ROFECOXIB; TRANSFORMING GROWTH FACTOR BETA;

ACUTE PANCREATITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC PANCREATITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GENETIC CODE; HISTOPATHOLOGY; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; WILD TYPE;

ACTINS; AGE FACTORS; ANIMALS; CAERULEIN; COLLAGEN; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; LACTONES; MICE; MICE, KNOCKOUT; PANCREAS; PANCREATITIS, CHRONIC; SPECIES SPECIFICITY; SULFONES; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA;

EID: 79957948001     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00497.2010     Document Type: Article

References (22)

1. Ding XZ, Tong WG, Adrian TE. Blockade of cyclooxygenase-2 inhibits proliferation and induces apoptosis in human pancreatic cancer cells. Anticancer Res 20: 2625-2631, 2000.
2. Emery P. Clinical implications of selective cyclooxygenase-2 inhibition. Scand J Rheumatol Suppl 102: 23-28, 1996.
3. Ethridge RT, Chung DH, Slogoff M, Ehlers RA, Hellmich MR, Rajaraman S, Saito H, Uchida T, Evers BM. Cyclooxygenase-2 gene disruption attenuates the severity of acute pancreatitis and pancreatitisassociated lung injury. Gastroenterology 123: 1311-1322, 2002.
4. Graf R, Schiesser M, Lussi A, Went P, Scheele GA, Bimmler D. Coordinate regulation of secretory stress proteins (PSP/reg, PAP I, PAP II, and PAP III) in the rat exocrine pancreas during experimental acute pancreatitis. J Surg Res 105: 136-144, 2002.
5. Koliopanos A, Friess H, Kleeff J, Roggo A, Zimmermann A, Buchler MW. Cyclooxygenase 2 expression in chronic pancreatitis: correlation with stage of the disease and diabetes mellitus. Digestion 64: 240-247, 2001.
6. Lin JA, Watanabe J, Rozengurt N, Narasimha A, Martin MG, Wang J, Braun J, Langenbach R, Reddy ST. Atherogenic diet causes lethal ileo-ceco-colitis in cyclooxygenase-2 deficient mice. Prostaglandins Other Lipid Mediat 84: 98-107, 2007.
7. Morham SG, Langenbach R, Loftin CD, Tiano HF, Vouloumanos N, Jennette JC, Mahler JF, Kluckman KD, Ledford A, Lee CA, Smithies O. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell 83: 473-482, 1995.
8. Morham SG, Langenbach R, Mahler J, Smithies O. Characterization of prostaglandin H synthase 2 deficient mice and implications for mechanisms of NSAID action. Adv Exp Med Biol 407: 131-138, 1997.
9. Neuschwander-Tetri BA, Bridle KR, Wells LD, Marcu M, Ramm GA. Repetitive acute pancreatic injury in the mouse induces procollagen alpha1(I) expression colocalized to pancreatic stellate cells. Lab Invest 80: 143-150, 2000.
10. Niijima M, Yamaguchi T, Ishihara T, Hara T, Kato K, Kondo F, Saisho H. Immunohistochemical analysis and in situ hybridization of cyclooxygenase-2 expression in intraductal papillary-mucinous tumors of the pancreas. Cancer 94: 1565-1573, 2002.
11. Reding T, Bimmler D, Perren A, Sun LK, Fortunato F, Storni F, Graf R. A selective COX-2 inhibitor suppresses chronic pancreatitis in an animal model (WBN/Kob rats): significant reduction of macrophage infiltration and fibrosis. Gut 55: 1165-1173, 2006.
12. Schlosser W, Schlosser S, Ramadani M, Gansauge F, Gansauge S, Beger HG. Cyclooxygenase-2 is overexpressed in chronic pancreatitis. Pancreas 25: 26-30, 2002.
13. Sheng H, Shao J, Kirkland SC, Isakson P, Coffey RJ, Morrow J, Beauchamp RD, DuBois RN. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase 2. J Clin Invest 99: 2254-2259, 1997.
14. Shi S, Klotz U. Clinical use and pharmacological properties of selective COX-2 inhibitors. Eur J Clin Pharmacol 64: 233-252, 2008.
15. Slogoff MI, Ethridge RT, Rajaraman S, Evers BM. COX-2 inhibition results in alterations in nuclear factor (NF)-kappaB activation but not cytokine production in acute pancreatitis. J Gastrointest Surg 8: 511-519, 2004.
16. Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 69: 145-182, 2000.
17. Song AM, Bhagat L, Singh VP, Van Acker GG, Steer ML, Saluja AK. Inhibition of cyclooxygenase-2 ameliorates the severity of pancreatitis and associated lung injury. Am J Physiol Gastrointest Liver Physiol 283: G1166-G1174, 2002.
18. Sun LK, Reding T, Bain M, Heikenwalder M, Bimmler D, Graf R. Prostaglandin E2 modulates TNF-alpha-induced MCP-1 synthesis in pancreatic acinar cells in a PKA-dependent manner. Am J Physiol Gastrointest Liver Physiol 293: G1196-G1204, 2007.
19. Tucker ON, Dannenberg AJ, Yang EK, Zhang F, Teng L, Daly JM, Soslow RA, Masferrer JL, Woerner BM, Koki AT, Fahey TJ 3rd. Cyclooxygenase-2 expression is up regulated in human pancreatic cancer. Cancer Res 59: 987-990, 1999.
20. van Westerloo DJ, Florquin S, de Boer AM, Daalhuisen J, de Vos A, Bruno MJ, van der Poll T. Therapeutic effects of troglitazone in experimental chronic pancreatitis in mice. Am J Pathol 166: 721-728, 2005.
21. Watanabe J, Lin JA, Narasimha AJ, Shahbazian A, Ishikawa TO, Martin MG, erschman HR, Reddy ST. Novel anti-inflammatory functions for endothelial and myeloid yclooxygenase-2 in a new mouse model of Crohn's disease. Am J Physiol Gastrointest iver Physiol 298: G842-G850, 2010.
22. Yoo BM, Oh TY, Kim YB, Yeo M, Lee JS, Surh YJ, Ahn BO, Kim WH, Sohn S, im JH, Hahm KB. Novel antioxidant ameliorates the ibrosis and inflammation of cerulein-induced chronic pancreatitis in a mouse model. Pancreatology 5: 165-176, 2005.